Bedel Financial Consulting, Inc. Iterum Therapeutics PLC Call Options Transaction History

Bedel Financial Consulting, Inc.

  • $691 Million
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding ITRM

# of Institutions
1
Shares Held
66
Call Options Held
0
Put Options Held
0
View Full List

About Iterum Therapeutics plc

ITRM Quotes by TradingView
  • Ticker ITRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,233,400
  • Market Cap $13.7M
  • Description
  • Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...
More about ITRM
Track This Portfolio

Track Bedel Financial Consulting, Inc. Portfolio

Follow Bedel Financial Consulting, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email